Two of the most distressing side effects of cancer treatment, nausea and vomiting, cause enough fear in some patients to induce them to delay or abandon potentially curative treatment. Some studies of surgical patients suggest that the fear of
Two of the most distressing side effects of cancer treatment, nausea and vomiting, cause enough fear in some patients to induce them to delay or abandon potentially curative treatment. Some studies of surgical patients suggest that the fear of nausea and vomiting is even greater than the fear of postoperative pain.
To help health care professionals provide care for these patients, Hoechst Marion Roussel, launched the Anzemet (dolasetron mesylate injection/tablets) Information Center at www.anzemet.com.
The web site provides:
Information on the prevention of chemotherapy-induced nausea and vomiting and the prevention and treatment of postoperative nausea and vomiting;
Access to dolasetron product information, including information on the pharmacology, efficacy, safety, and administration of dolasetron;
Data on the pharmacology, efficacy, safety, and administration of dolasetron;
Information about the Anzemet Reimbursement and Patient Assistance programs
Educational resources for cancer patients
Hoechst Marion Roussel also developed two patient education pamphlets that can be accessed in the Professional Resources area of the site. "Working Your Way Through Chemotherapy: Advice From A Good Friend" addresses the specific issues of cancer patients who continue to work while undergoing chemotherapy. "Speaking From Experience: Insights From Cancer Survivors and Their Families" informs patients and families about what chemotherapy is like and how to get and give help during chemotherapy.
Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative Oncology
September 20th 2022Authors Dori Beeler, PhD; Shelley Wang, MD, MPH; and Viraj A. Master, MD, PhD, spoke with CancerNetwork® about a review article on cancer-related fatigue published in the journal ONCOLOGY®.